Psychiatry and Neurology, Neurology · Longmont, CO
NPI
1669977997
Since 2018
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
3
Medicare group memberships
Hospitals
5
Hospital affiliations
1925 Mountain View Ave
Longmont, CO, 80501
Phone (720) 718-8070
Groups this clinician bills Medicare through
Medicare paid, 2024
$48K
1,173 services
Medicare patients, 2024
201
Average age 72
Drug cost, 2024
$390K
957 prescriptions
Company payments, 2025
$1,104
From 3 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Anthony R Declusin was code G2211 (visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's), 93 times for 78 patients. In total Anthony R Declusin billed 1,173 services in 26 codes, and Medicare paid $48K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-07-06.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|---|---|---|---|---|
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 93 | 78 | $12.78 | $1,188 |
| 99215 Office E&M - Established | Office | 92 | 72 | $133.14 | $12K |
| 99205 Office E&M - New | Office | 91 | 91 | $164.56 | $15K |
| 99214 Office E&M - Established | Office | 79 | 58 | $93.22 | $7,364 |
| G2212 Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 72 | 41 | $25.12 | $1,809 |
| 36415 Venipuncture Blood Collection | Office | 44 | 37 | $8.65 | $381 |
| 99204 Office E&M - New | Office | 34 | 34 | $115.94 | $3,942 |
| 99203 Office E&M - New | Office | 12 | 12 | $72.28 | $867 |
By year: 2022 $2,732 for 35 services; 2023 $19K for 400 services; 2024 $48K for 1,173 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 44 | 37 | $8.65 | $381 |
Medicare prescription drug claims, 2024
In 2024, the drug Anthony R Declusin prescribed most often to Medicare patients was Gabapentin, with 90 prescriptions and refills. In total Anthony R Declusin wrote 957 Medicare prescriptions that cost $390K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Gabapentin Generic | 90 | 225 | 43 | $2,483 |
| Donepezil Hcl Generic | 79 | 231 | 37 | $884 |
| Carbidopa-Levodopa Carbidopa/Levodopa | 72 | 201 | 25 | $2,839 |
| Nortriptyline Hcl Generic | 62 | 172 | 23 | $1,631 |
| Baclofen Generic | 42 | 90 | 20 | $1,801 |
| Topiramate Generic | 37 | 91 | 18 | $741 |
| Rizatriptan Rizatriptan Benzoate | 32 | 37 | 18 | $452 |
| Pregabalin Generic | 28 | 75 | 17 | $662 |
| Levetiracetam Generic | 25 | 71 | 11 | $1,344 |
| Diazepam Generic | 23 | 23 | 11 | $95.53 |
| Atorvastatin Calcium Generic | 23 | 53 | Under 11 | $192 |
| Amitriptyline Hcl Generic | 22 | 64 | 12 | $297 |
| Propranolol Hcl Generic | 19 | 57 | 11 | $466 |
| Memantine Hcl Generic | 18 | 54 | Under 11 | $477 |
| Copaxone Glatiramer Acetate | 18 | 18 | Under 11 | $103K |
Brand drugs: - claims; generic drugs: 868 claims; opioid claims: 15.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Anthony R Declusin $1,104 ($1,104 in general payments such as food, travel and fees) from 3 companies. The largest payer was TG Therapeutics, Inc. with $848.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.